Comparative Pharmacology
Head-to-head clinical analysis: VALIUM versus ZAXOPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALIUM versus ZAXOPAM.
VALIUM vs ZAXOPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzodiazepine that enhances the effect of GABA at GABA-A receptors, increasing chloride ion conductance and producing neuronal hyperpolarization.
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
Oral: 2-10 mg 2-4 times daily. IV/IM: 5-10 mg, repeat in 3-4 hours if needed; max 30 mg in 8 hours.
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
None Documented
None Documented
Terminal elimination half-life of diazepam: 20–50 hours; active metabolite desmethyldiazepam half-life: 36–200 hours (accumulates with chronic dosing, prolonging clinical effects).
Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients.
Renal: <1% unchanged; hepatic metabolism to active metabolites (desmethyldiazepam, temazepam, oxazepam); metabolites excreted renally as glucuronides. Fecal: minor.
Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%.
Category C
Category C
Benzodiazepine
Benzodiazepine